Literature DB >> 24227842

APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation.

Zhe Wang1, Kousho Wakae, Kouichi Kitamura, Satoru Aoyama, Guangyan Liu, Miki Koura, Ahasan M Monjurul, Iwao Kukimoto, Masamichi Muramatsu.   

Abstract

Apolipoprotein B mRNA-editing catalytic polypeptide 3 (APOBEC3) proteins are interferon (IFN)-inducible antiviral factors that counteract various viruses such as hepatitis B virus (HBV) and human immunodeficiency virus type 1 (HIV-1) by inducing cytidine (C)-to-uracil (U) mutations in viral DNA and inhibiting reverse transcription. However, whether APOBEC3 proteins (A3s) can hypermutate human papillomavirus (HPV) viral DNA and exhibit antiviral activity in human keratinocyte remains unknown. Here we examined the involvement of A3s in the HPV life cycle using cervical keratinocyte W12 cells, which are derived from low-grade lesions and retain episomal HPV16 genomes in their nuclei. We focused on the viral E2 gene as a potential target for A3-mediated hypermutation because this gene is frequently found as a boundary sequence in integrated viral DNA. Treatment of W12 cells with beta interferon (IFN-β) increased expression levels of A3s such as A3A, A3F, and A3G and induced C-to-U conversions in the E2 gene in a manner depending on inhibition of uracil DNA glycosylase. Exogenous expression of A3A and A3G also induced E2 hypermutation in W12 cells. IFN-β-induced hypermutation was blocked by transfection of small interfering RNAs against A3G (and modestly by those against A3A). However, the HPV16 episome level was not affected by overexpression of A3A and A3G in W12 cells. This study demonstrates that endogenous A3s upregulated by IFN-β induce E2 hypermutation of HPV16 in cervical keratinocytes, and a pathogenic consequence of E2 hypermutation is discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24227842      PMCID: PMC3911654          DOI: 10.1128/JVI.03091-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses.

Authors:  Reuben S Harris; Ann M Sheehy; Heather M Craig; Michael H Malim; Michael S Neuberger
Journal:  Nat Immunol       Date:  2003-07       Impact factor: 25.606

Review 2.  Retroviral restriction by APOBEC proteins.

Authors:  Reuben S Harris; Mark T Liddament
Journal:  Nat Rev Immunol       Date:  2004-11       Impact factor: 53.106

3.  Properties of a non-tumorigenic human cervical keratinocyte cell line.

Authors:  M A Stanley; H M Browne; M Appleby; A C Minson
Journal:  Int J Cancer       Date:  1989-04-15       Impact factor: 7.396

Review 4.  DNA deamination in immunity.

Authors:  Svend Petersen-Mahrt
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

5.  DNA cleavage in immunoglobulin somatic hypermutation depends on de novo protein synthesis but not on uracil DNA glycosylase.

Authors:  Hitoshi Nagaoka; Satomi Ito; Masamichi Muramatsu; Mikiyo Nakata; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

6.  Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.

Authors:  Rodolphe Suspène; Denise Guétard; Michel Henry; Peter Sommer; Simon Wain-Hobson; Jean-Pierre Vartanian
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

7.  The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.

Authors:  Keisuke Shindo; Akifumi Takaori-Kondo; Masayuki Kobayashi; Aierken Abudu; Keiko Fukunaga; Takashi Uchiyama
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

8.  Uracil DNA glycosylase activity is dispensable for immunoglobulin class switch.

Authors:  Nasim A Begum; Kazuo Kinoshita; Naoki Kakazu; Masamichi Muramatsu; Hitoshi Nagaoka; Reiko Shinkura; Detlev Biniszkiewicz; Laurie A Boyer; Rudolf Jaenisch; Tasuku Honjo
Journal:  Science       Date:  2004-08-20       Impact factor: 47.728

9.  APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.

Authors:  Hui Chen; Caroline E Lilley; Qin Yu; Darwin V Lee; Jody Chou; Iñigo Narvaiza; Nathaniel R Landau; Matthew D Weitzman
Journal:  Curr Biol       Date:  2006-03-07       Impact factor: 10.834

10.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

View more
  37 in total

1.  Family-Wide Comparative Analysis of Cytidine and Methylcytidine Deamination by Eleven Human APOBEC Proteins.

Authors:  Fumiaki Ito; Yang Fu; Shen-Chi A Kao; Hanjing Yang; Xiaojiang S Chen
Journal:  J Mol Biol       Date:  2017-05-04       Impact factor: 5.469

Review 2.  Functions and Malfunctions of Mammalian DNA-Cytosine Deaminases.

Authors:  Sachini U Siriwardena; Kang Chen; Ashok S Bhagwat
Journal:  Chem Rev       Date:  2016-09-01       Impact factor: 60.622

Review 3.  Evasion of host immune defenses by human papillomavirus.

Authors:  Joseph A Westrich; Cody J Warren; Dohun Pyeon
Journal:  Virus Res       Date:  2016-11-24       Impact factor: 3.303

4.  Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.

Authors:  Candace D Middlebrooks; A Rouf Banday; Konichi Matsuda; Krizia-Ivana Udquim; Olusegun O Onabajo; Ashley Paquin; Jonine D Figueroa; Bin Zhu; Stella Koutros; Michiaki Kubo; Taro Shuin; Neal D Freedman; Manolis Kogevinas; Nuria Malats; Stephen J Chanock; Montserrat Garcia-Closas; Debra T Silverman; Nathaniel Rothman; Ludmila Prokunina-Olsson
Journal:  Nat Genet       Date:  2016-09-19       Impact factor: 38.330

Review 5.  Current and Emerging Molecular Tests for Human Papillomavirus-Related Neoplasia in the Genomic Era.

Authors:  Sixto M Leal; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2017-03-18       Impact factor: 5.568

6.  APOBEC3A functions as a restriction factor of human papillomavirus.

Authors:  Cody J Warren; Tao Xu; Kejun Guo; Laura M Griffin; Joseph A Westrich; Denis Lee; Paul F Lambert; Mario L Santiago; Dohun Pyeon
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

7.  APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers.

Authors:  S Kondo; K Wakae; N Wakisaka; Y Nakanishi; K Ishikawa; T Komori; M Moriyama-Kita; K Endo; S Murono; Z Wang; K Kitamura; T Nishiyama; K Yamaguchi; S Shigenobu; M Muramatsu; T Yoshizaki
Journal:  Oncogene       Date:  2016-10-03       Impact factor: 9.867

8.  Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.

Authors:  Sara Pautasso; Ganna Galitska; Valentina Dell'Oste; Matteo Biolatti; Rachele Cagliani; Diego Forni; Marco De Andrea; Marisa Gariglio; Manuela Sironi; Santo Landolfo
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

Review 9.  Host cell restriction factors that limit transcription and replication of human papillomavirus.

Authors:  Samuel S Porter; Wesley H Stepp; James D Stamos; Alison A McBride
Journal:  Virus Res       Date:  2016-11-15       Impact factor: 3.303

Review 10.  Interactions of APOBEC3s with DNA and RNA.

Authors:  Atanu Maiti; Shurong Hou; Celia A Schiffer; Hiroshi Matsuo
Journal:  Curr Opin Struct Biol       Date:  2021-01-22       Impact factor: 6.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.